Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Viking Therapeutics, Inc. - Common Stock (NQ: VKTX )

29.73 +0.18 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Why Viking Therapeutics Stock Is Trading Higher Tuesday
Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company announced positive top-line results from a Phase 
Via Benzinga
Why Viking Therapeutics Stock Wobbled Today
The biotech's shares dipped along with the broader markets in early-morning trading today. 
Via The Motley Fool
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
These three biotech stocks were on the volatile side today. 
Via The Motley Fool
Why Viking Therapeutics Stock Briefly Popped Today
The biotech's shares rose briefly this morning following a sizable price target revision by an investing firm. 
Via The Motley Fool
Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water
Mounjaro topped first-quarter sales expectations by more than $100 million. 
Via Investor's Business Daily
Earnings Scheduled For April 26, 2023
Companies Reporting Before The Bell • Teck Resources (NYSE:TECK) is expected to report quarterly earnings at $1.36 per share on revenue of $3.11 billion. 
Via Benzinga
Expert Ratings for Viking Therapeutics
Via Benzinga
Earnings Preview For Viking Therapeutics
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs
The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme 
Via MarketBeat
Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook
Demand for Wegovy and Ozempic prompted Novo to raise its full-year outlook. 
Via Investor's Business Daily
Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $725 Million Deal
Novo Nordisk is already a leader in obesity treatment with Saxenda and Wegovy. 
Via Investor's Business Daily
Why Shares of Viking Therapeutics Skyrocketed This Week
The clinical-stage stock nearly doubled in price. 
Via The Motley Fool
BTIG Maintains Buy Rating for Viking Therapeutics: Here's What You Need To Know
Via Benzinga
Viking Therapeutics Steps Into The Obesity Ring — And Catapults 63%
The company is taking on rivals Novo Nordisk, Eli Lilly and Amgen. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
5 Best Stocks to Buy in April
These powerful trends should yield stellar returns for investors in April and beyond. 
Via The Motley Fool
Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review
The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica. 
Via Investor's Business Daily
RH, Semtech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Semtech Corporation (NASDAQ: SMTC) shares dipped 12.7% to $28.00 in... 
Via Benzinga
Tesla, RH, Rumble, Stem, Viking Therapeutics: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
The Government Move That Could Drive Obesity Drugs — And Lilly, Novo Shares
The decision from the WHO could further bolster use of Novo's Saxenda and Wegovy. 
Via Investor's Business Daily
Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday. 
Via Benzinga
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
Viking Therapeutics stock might in the midst of a historic run. 
Via The Motley Fool
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making. 
Via The Motley Fool
Viking Therapeutics' Initial VK2735 'Data Resoundingly Beat Expectations,' Analyst Says
Earlier today, Viking Therapeutics Inc (NASDAQ: VKTX) announced the first-in-human single-ascending dose and multiple-ascending dose data of VK2735. 
Via Benzinga
Nasdaq Dips 90 Points; Walgreens Posts Upbeat Q2 Results
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 90 points on Tuesday. The Dow traded down 0.21% to 32,362.74 while the NASDAQ fell 0.77% to 11,678.39. The... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Viking Therapeutics Inc. (NASDAQ: VKTX) Records 52-Week High Tuesday Morning
Via Investor Brand Network
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP 
Via MarketBeat
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.